Skeletal muscle abnormalities, including sarcopenia (pathological muscle mass depletion) and myosteatosis (abnormal fat accumulation in the muscles) are common features in patients with cirrhosis. Recently, sarcopenia has become increasingly recognized as a complication of cirrhosis and a prognostic factor for worse outcome. Several studies, particularly in the setting of the waiting list for liver transplantation (LT) have identified sarcopenia as a risk factor for drop-out from the waiting list [1], peri‑ and post-surgical complications and mortality [2].
